Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 653 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Total Cholesterol Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

NCT04785144
View directory record Official record
Conditions
COVID-19, COVID-19 Immunisation
Interventions
mRNA-1273, mRNA-1273.351
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Decatur, Georgia • Cincinnati, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Nov 14, 2026, 5:57 AM EST
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

NCT04546126
View directory record Official record
Conditions
Radiotracer, Hypertension, Cholesterol
Interventions
Dexamethasone (Group 2), Cosyntropin (Group 3), PET/CT Scan with FNP-59
Drug · Combination Product
Lead sponsor
Benjamin Viglianti
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 2 Interventional

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

NCT01058018
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 3 Interventional Results available

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

NCT01156597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pioglitazone
Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 2 Interventional

Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus

NCT00403533
View directory record Official record
Conditions
Hepatitis C
Interventions
20 mg of atorvastatin daily
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2006 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 1Phase 2 Interventional

A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients

NCT00299338
View directory record Official record
Conditions
HIV Infections
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2006 · Synced Nov 14, 2026, 5:57 AM EST
Completed No phase listed Observational

An Observational Study of Cholesterol in Coronary Arteries

NCT00831116
View directory record Official record
Conditions
Myocardial Infarction, Angina, Coronary Artery Disease, Myocardial Ischemia
Interventions
Intravascular Near Infrared Spectroscopy
Device
Lead sponsor
Infraredx
Industry
Eligibility
18 Years and older
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
22
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

NCT02991118
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid, placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Clearwater, Florida • Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Nov 14, 2026, 5:57 AM EST
Completed No phase listed Observational

An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype

NCT01528917
View directory record Official record
Conditions
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
5 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 2 Interventional

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00281008
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
ISIS 301012 or Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Nov 14, 2026, 5:57 AM EST
Recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

NCT07619131
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin, Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Placebo to match Laroprovstat/Rosuvastatin 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
77
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 14, 2026, 5:57 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol

NCT01200836
View directory record Official record
Conditions
Healthy Volunteers, Statins, Immune Modulation
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Nov 14, 2026, 5:57 AM EST
Completed Not applicable Interventional

Asian American Partnerships in Research and Empowerment (AsPIRE)

NCT03100812
View directory record Official record
Conditions
Hypertensive Heart Disease, Hypertension
Interventions
More intensive CHW Intervention, Less Intensive CHW Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 25 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Nov 14, 2026, 5:57 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Black Tea Intake on Serum Lipids

NCT01882283
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Tea Treatment Group, Placebo
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Nov 14, 2026, 5:57 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise, Statins, and the Metabolic Syndrome

NCT01700530
View directory record Official record
Conditions
Metabolic Syndrome, Obese, Sedentary
Interventions
Statin, Exercise only, Statins + Exercise
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
25 Years to 59 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Nov 14, 2026, 5:57 AM EST
Completed Early Phase 1 Interventional

Treating Congestive Heart Failure Using a Device to Remove Cholesterol

NCT00510601
View directory record Official record
Conditions
Heart Decompensation
Interventions
Kaneka Liposorber
Device
Lead sponsor
Patrick Moriarty, MD, FACP, FACC
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Nov 14, 2026, 5:57 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Exome Sequencing in Autistic Spectrum Disorder

NCT01059201
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Autistic Disorder
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
322 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 14, 2026, 5:57 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Orange Juice And Sugar Intervention Study

NCT03527277
View directory record Official record
Conditions
Cardiovascular Risk Factor, Type2 Diabetes Mellitus, Insulin Sensitivity, Metabolic Syndrome
Interventions
Naturally-sweetened orange juice, Sugar-sweetened beverage
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 14, 2026, 5:57 AM EST
Terminated Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

NCT00267280
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
Interventions
torcetrapib/atorvastatin, simvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Alhambra, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Nov 14, 2026, 5:57 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Beef Burger Versus a Vegetarian Burger

NCT04034160
View directory record Official record
Conditions
Inflammation
Interventions
vegetarian burger, beef burger
Other
Lead sponsor
Loma Linda University
Other
Eligibility
21 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Nov 14, 2026, 5:57 AM EST
Completed Not applicable Interventional

Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents

NCT05268042
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Moderately carbohydrate-restricted diet, Fat-restricted diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Asahi Kasei Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 14, 2026, 5:57 AM EST
Completed Phase 1Phase 2 Interventional

Dietary Intervention With the Modified Atkins Diet in Stroke Rehabilitation

NCT01820663
View directory record Official record
Conditions
Stroke, Ischemic Stroke
Interventions
Modified Atkins Diet, Control diet
Other
Lead sponsor
Burke Rehabilitation Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Nov 14, 2026, 5:57 AM EST